Efficacy of a nucleoside-sparing regimen of darunavir/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)

AIDS

Volumn 25, Issue 17, 2011, Pages 2113-2122

  Taiwo, Babafemi ^a   Zheng, Lu ^b   Gallien, Sebastien ^c   Matining, Roy M ^b   Kuritzkes, Daniel R ^c   Wilson, Cara C ^d   Berzins, Baiba I ^a   Acosta, Edward P ^e   Bastow, Barbara ^f   Kim, Peter S ^g   Eron, Joseph J ^h  

^a NORTHWESTERN UNIVERSITY   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c BRIGHAM AND WOMEN S HOSPITAL   (United States)

^d UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^e University of Alabama at Birmingham   (United States)

^f SOCIAL AND SCIENTIFIC SYSTEMS INC   (United States)

^g NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^h UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Antiretroviral therapy; Darunavir; Nucleoside sparing; Raltegravir

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; DARUNAVIR; INTEGRASE; PROTEINASE; RALTEGRAVIR; RITONAVIR;

ABDOMINAL PAIN; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSLIPIDEMIA; FEMALE; GENE MUTATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; INTENTION TO TREAT ANALYSIS; MACULOPAPULAR RASH; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SIDE EFFECT; VIRUS LOAD;

ADOLESCENT; ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; ODDS RATIO; PYRROLIDINONES; RITONAVIR; RNA, VIRAL; SULFONAMIDES; TREATMENT OUTCOME; VIRAL LOAD; YOUNG ADULT;

EID: 80055028058     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0b013e32834bbaa9     Document Type: Article

References (30)

1. Panel on Antireroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1 infected adults and adolescents. Department of Health and Human Services. 2011. http://aidsinfo.nih.gov/ contentfiles/Adultand AdolescentGL.pdf. [Accessed 8 April 2011]
2. Wittkop L, Gunthard HF, de Wolf F, Dunn D, Cozzi-Lepri A, de Luca A, et al. Effect of transmitted resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study. Lancet Infect Dis 2011; 11:363-371.
3. Riddler SA, Haubrich R, DiRienzo AG, Peeples L, Powderly WG, Klingman KL, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med 2008; 358:2095-2106. (Pubitemid 351679596)
4. Mills AM, Nelson M, Jayaweera D, Ruxrungtham K, Cassetti I, Girard PM, et al. Once-daily darunavir/ritonavir vs. lopinavir/ ritonavir in treatment-naive, HIV-1-infected patients: 96-week analysis. AIDS 2009; 23:1679-1688.
5. Lennox JL, DeJesus E, Berger DS, Lazzarin A, Pollard RB, Ramalho Madruga JV, et al. Raltegravir versus efavirenz regimens in treatment-na?̈ve HIV-1 infected patients: 96 week efficacy, durability, subgroup, safety and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55:39-48.
6. Chesney MA, Ickovics JR, Chambers DB, Gifford AL, Neidig J, Zwickl B, Wu AW. Self-reported adherence to antiretroviral medications among participants in HIV clinical trials: the AACTG adherence instrument. Patient Care Committee and Adherence Working Group of the Outcomes Committee of the Adult AIDS Clinical Trials Group (AACTG). AIDS Care 2000; 12:255-266.
7. Johnson VA, Brun-Vezinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, et al. Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med 2009; 17:138-145.
8. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: Wiley; 1980.
9. Markowitz M, Nguyen BY, Gotuzzo E, Mendo F, Ratanasuwan W, Kovacs C, et al. Rapid and durable antiretroviral effects of the HIV-1 integrase inhibitor raltegravir as part of combination therapy in treatment-na?̈ve patients with hIV-1 infection: results of a 48-week controlled study. J Acquir Immune Defic Syndr 2007; 46:125-133. (Pubitemid 47482607)
10. Gulick RM, Ribaudo HJ, Shikuma CM, Lalama C, Schackman BR, Meyer WA 3rd, et al. Three- vs four-drug antiretroviral regimens for the initial treatment of HIV-1 infection: a randomized controlled trial. JAMA 2006; 296:769-781. (Pubitemid 44223101)
11. Division of AIDS Table for Grading the Severity of Adult and Pediatric Adverse Events. December 2004. http://www.niaid.nih. gov/LabsAndResources/ resources/DAIDSClinRsrch/Documents/ daidsaegradingtable.pdf [Accessed 2 April 2011]
12. Brouwer ES, Napravnik S, Smiley SG, Corbett AH, Eron JJ. Self-report of current and prior antiretroviral drug use in comparison to the medical record among HIV-infected patients receiving primary care. Pharmacoepidemiol Drug Safety 2011; 20:432-439.
13. Eron J, Rockstroh J, Reynes J, Andrade-Villanueva J, Madruga J, Zhao J, et al. QDMRK, a phase III study of the safety and efficacy of once daily (QD) versus twice daily (BID) raltegravir (RAL) in combination therapy for treatment-na?̈ve HIVinfected patients. In: Abstracts of 18th Conference on Retroviruses and Opportunistic Infections; Boston, MA; February 27 to March 2 2011; abstract 150L.
14. Fabbiani M, Di Giambenedetto S, Ragazzoni E, D'Ettorre G, Parruti G, Prosperi M, et al. Darunavir/ritonavir and raltegravir coadministered in routine clinical practice: Potential role for an unexpected drug interaction. Pharmacol Res 2011; 63:249-253.
15. Boffito M, Moyle M, Hill A, Sekar V, Lefebvre E, De Pauw M, et al. The pharmacokinetic profile of darunavir with low-dose ritonavir (DRV/r) in various multiple-dose regimens over 120 h. In: Abstracts of the 9th International Workshop on Clinical Pharmacology of HIV Therapy; New Orleans, 7-9 April 2008; abstract P31.
16. Yan CS, Hanafi I, Kelleher AD, Carr AD, Amin J, McNally LP, et al. Lack of correlation between three commercial platforms for the evaluation of human immunodeficiency virus type 1 (HIV-1) viral load at the clinically critical lower limit of quantification. J Clin Virol 2010; 49:249-253.
17. Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, et al. Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral- na?̈ve HIV-1-infected patients: 48 weeks efficacy and safety results of the CASTLE study. Lancet 2008; 372:646-655.
18. Ortiz R, DeJesus E, Khanlou H,Voronin E, van Lunzen J, Andrade- Villanueva J, et al. Efficacy and safety of once-daily darunavir/ ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1- infected patients at week 48. AIDS 2008; 22:1389-1397.
19. Sax P, Tierney C, Collier AC, Fischl MA, Mollan K, Peeples L, et al. Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-2240.
20. Smith KY, Patel P, Fine D, Bellos N, Sloan L, Lackey P, et al. Randomized, double-blind, placebo-matched, multicenter trial of abacavir/lamivudine or tenofovir/emtricitabine with lopinavir/ritonavir for initial HIV treatment. AIDS 2009; 23:1547-1556.
21. van Leth F, Andrew S, Grinsztejn B, Wilkins E, Lazanas MK, Lange JM. Montaner J; 2NN study group. The effects of baseline CD4 cell count and HIV-1 viral load on the efficacy and safety of nevirpaine or efavirenz-based first-line HAART. AIDS 2005; 19:463-471. (Pubitemid 40515849)
22. Ribaudo H, Lennox J, Currier J, Kuritzkes D, Gulick R, Haubrich R, et al. Virologic failure endpoint definition in clinical trials: is using HIV-1 RNA threshold < 200 copies/mL better than < 50 copies/mL? An analysis of ACTG studies. In: Abstracts of 16th Conference on Retroviruses and Opportunistic Infections; Montreal; 8-11 February 2009; abstract 580.
23. Kozal MJ, Lupo S, DeJesus E, Molina J, McDonald C, Raffi F, et al. The SPARTAN Study: A pilot study to assess the safety and efficacy of an investigational NRTI-and RTV-sparing regimen of atazanavir (ATV) experimental dose of 300mg bid plus raltegravir 400mg bid ((ATV R RAL- in treatment-naïve HIV-1 infected subjects. In: Abstracts of XVIII International AIDS Conference; Vienna; 18-23 July 2010; abstract MOAB010.
24. Reynes J, Lawal A, Pulido F, Soto-Malave R, Gathe J, Tian M, et al. Lopinavir/ritonavir combined with raltegravir demonstrated similar antiviral efficacy and safety as lopinavir/ritonavir combined with tenofovir disoproxil fumarate/emtricitabine in treatment naive HIV-1 infected subjects: PROGRESS 48 week results. In: Abstracts of XVIII International AIDS Conference; Vienna; 18-23 July 2010; abstract THLBB204.
25. Charpentier C, Laureillard D, Piketty C, Tisserand P, Batisse D, Karmochkine M, et al. High frequency of integrase Q148R minority variants in HIV-infected patients na?̈ve of integrase inhibitors. AIDS 2010; 24:867-873.
26. Lui J, Miller MD, Danovich RM, Vandergrift N, Cai F, Hicks CB, et al. Analysis of low-frequency mutations associated with drug resistance to raltegravir before antiretroviral treatment. Antimicrob Agents Chemother 2011; 55:1114-1119.
27. Taiwo B, Gallien S, Aga E, Ribaudo H, Haubrich R, Kuritzkes DR, Eron JJ. Antiretroviral drug resistance in HIV-1-infected patients experiencing persistent low-level viremia during firstline therapy. J Infect Dis 2011; 204:515-520.
28. Gallien S, Delaugerre C, Charreau I, Braun J, Boulet T, Barrail- Tran A, et al. Emerging integrase inhibitor resistance mutations in raltegravir-treated HIV-1-infected patients with low-level viremia. AIDS 2011; 25:655-659.
29. Hirsch MS, Gunthard HF, Schapiro JM, Brun-Vezinet F, Clotet B, Hammer SM, et al. Antiretroviral drug resistance testing in adult HIV-1 infection: 2008 recommendations of an International AIDS Society-USA panel. Clin Infect Dis 2008; 47:266-285. (Pubitemid 351920631)
30. Young B, Fransen S, Greenberg KS, Thomas A, Martens S, St Clair M, et al. Transmission of integrase strand-transfer inhibitor multidrug resistant HIV: case report and natural history of response raltegravir-containing antiretroviral therapy. Antiviral Ther 2011; 16:253-256.